BCMA-NFκB Luciferase Reporter HEK293 Cell Line

Description

BCMA-NFκB Luciferase Reporter HEK293 Cell Line is a genetically engineered reporter system designed to study BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) signaling through their shared receptor BCMA (B-cell maturation antigen). This stable HEK293 cell line features a NFκB-responsive luciferase reporter coupled with exogenous BCMA expression, enabling sensitive quantification of BAFF/APRIL-induced NFκB activation. The cell line demonstrates dose-dependent luminescence upon stimulation with either BAFF or APRIL, providing a robust platform for studying BCMA-mediated signaling, screening therapeutic antibodies, and evaluating drug candidates targeting this critical pathway in B-cell development and multiple myeloma. Maintained at low passages (<P20) to ensure reporter stability, this system offers consistent performance for both research and drug discovery applications. The cells are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, mycoplasma, Fungi, Yeast and Bacteria.

Application

• FOR RESEARCH USE ONLY
  

• The BCMA-NFκB Luciferase Reporter HEK293 Cell Line is an engineered cell model designed to study B-cell maturation antigen (BCMA)-mediated NFκB signaling activation. This system features stable co-expression of human BCMA and an NFκB-responsive luciferase reporter, enabling quantitative measurement of pathway activity upon ligand stimulation (e.g., BAFF, APRIL) or therapeutic intervention. The cell line provides a sensitive platform for evaluating BCMA-targeted therapies (including CAR-T, bispecific antibodies, and proteolysis-targeting chimeras) and investigating BCMA signaling mechanisms. Maintain in DMEM with 10% FBS and appropriate selection antibiotics to ensure consistent reporter performance.